Russell Investments Group Ltd. Acquires 26,506 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Russell Investments Group Ltd. grew its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 323.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 34,706 shares of the biopharmaceutical company's stock after acquiring an additional 26,506 shares during the quarter. Russell Investments Group Ltd.'s holdings in TG Therapeutics were worth $1,045,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp increased its position in shares of TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after buying an additional 1,737 shares during the period. Synergy Asset Management LLC bought a new position in TG Therapeutics during the fourth quarter worth $75,000. Finally, GAMMA Investing LLC lifted its holdings in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 2,171 shares during the period. Institutional investors own 58.58% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Stock Up 2.6 %

TG Therapeutics stock traded up $1.03 during midday trading on Friday, hitting $41.33. 1,464,365 shares of the stock were exchanged, compared to its average volume of 3,085,138. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $6.56 billion, a price-to-earnings ratio of -413.26 and a beta of 2.14. The business's 50-day moving average price is $37.18 and its 200-day moving average price is $32.45. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.